Table 2 Clinical characteristics of the candidaemia cohort.
From: Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia
Variable | Controls | Patients | P-value |
|---|---|---|---|
Mean age (s.d.) (years) | 60.2 (17.5) | 54.7 (20.2) | 0.01 |
Male gender (%) | 49.3 | 64.0 | 0.008 |
Immunocompromised state (%) | 36.3 | 61.7 | <0.0001 |
Hematopoietic stem cell transplantation (%) | 0 | 2.8 | 0.06 |
Solid organ transplant (%) | 0.7 | 15.4 | <0.0001 |
Active malignancy* (%) | 21.9 | 35.0 | 0.008 |
Solid tumour | 12.3 | 26.0 | |
Leukaemia | 6.2 | 5.7 | |
Lymphoma | 4.1 | 4.0 | |
Chemotherapy within the past 3 months (%) | 12.3 | 18.9 | 0.11 |
Neutropenia (ANC<500 cells per mm3) (%) | 2.7 | 10.3 | 0.008 |
HIV-infected (%) | 0 | 0 | — |
Surgery within the past 30 days (%) | 56.2 | 49.1 | 0.21 |
Receipt of total parenteral nutrition (%) | 3.4 | 21.5 | <0.0001 |
Dialysis dependent (%) | 4.1 | 11.6 | 0.02 |
Acute renal failure (%) | 15.8 | 31.6 | 0.001 |
Liver disease (%) | 2.8 | 19.4 | <0.0001 |
Intensive care unit admission within the past 14 days | 34.2 | 54.4 | 0.0003 |
Candida spp.† (%) | |||
albicans | 43 | ||
glabrata | 27 | ||
parapsilosis | 16 | ||
tropicalis | 13 | ||
krusei | 3 | ||
Other Candida spp. | 4 | ||
Baseline serum creatinine, mean (s.d.) (mg dl−1) | 1.3 (1.0) | 1.6 (1.4) | 0.008 |
Baseline WBC count, mean (s.d.) (cells per mm3) | 10.6 (7.8) | 13.5 (13.7) | 0.02 |
